Home Members Dario Cattaneo

Dario Cattaneo

Associate Professor

Pharmacology

Associate Professor

E-mail

dario.cattaneo@hunimed.eu

Present academic appointment: Associate Professor in Pharmacology

Other institutional appointments: Clinical Pharmacologist, IRCCS Humanitas Research Hospital

Affiliations:

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

Department of Laboratory Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Education

High School Diploma in Chemistry, Bergamo, Italy (1984–1989)
Degree in Pharmacy, University of Milano, Italy (1990–1995)
Postgraduate Specialization in Pharmacological Research, Mario Negri Institute for Pharmacological Research, Bergamo, Italy (1997–2000)
Post-degree Specialization in Pharmacology, University of Milano, Italy (1998–2001)
PhD in Biomedical Sciences, Open University, London, UK (2001–2005)

Professional Experience

Research Fellow, Mario Negri Institute for Pharmacological Research, Bergamo, Italy (1997–2003)
Head, Unit of Pharmacology and Pharmacogenetics, Mario Negri Institute for Pharmacological Research, Bergamo, Italy (2004–2008)
Pharmacologist Member, Ethical Committee, Bolognini Hospital of Seriate, Bergamo, Italy (2003–2008)
Pharmacologist Member, Ethical Committee, Scientific Institute E. Medea, Bosisio Parini, Lecco, Italy (2004–2013)
Head, Laboratory of Pharmacokinetics and Therapeutic Drug Monitoring, Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milano, Italy (2008–2021)
Consultant Pharmacologist, ASST Fatebenefratelli Sacco University Hospital, Milano, Italy (2021–2025)
Co-Director of Outpatient Clinics for the Management of Polytherapy in complex Patients, Luigi Sacco University Hospital, Milano, Italy (2016–2025)
Member of the Executive Council and Immediate Past-President, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) (2019–Present)

Academic Appointments

Assistant Professor of Pharmacology, Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Italy (2010–2024)
Associate Professor of Pharmacology, Humanitas University, Milano, Italy (2025–Present)

Awards and Honors

E. Cofferati Award for Research in Immunosuppressant Pharmacology (2001)
D.E.I. Onlus Foundation Award for Emerging Excellence in Clinical Pharmacology (2010)
Italian Knowledge Leader Award, Convention Bureau Italia (2022)

Publications and Scientific Contributions

Author of over 320 peer-reviewed publications, cited more than 10,000 times (H-index: 48)
Contributor to 7 book chapters
Invited speaker at nearly 50 international and 300 national scientific congresses
Reviewer for approximately 50 indexed international journals, with over 500 manuscripts reviewed
Editorial Board Member of:
- European Journal of Drug Metabolism and Pharmacokinetics
- New Microbiologica
- Therapeutic Drug Monitoring
- Antibiotics

My primary areas of interest encompass human pharmacokinetic studies focused on characterizing the absorption, distribution, metabolism, and elimination profiles of xenobiotics in special patient populations, alongside the implementation of therapeutic drug monitoring (TDM) strategies aimed at optimizing dosing regimens, particularly for anti-infective agents, immunosuppressants, oncology drugs, and central nervous system medications.

In addition, I am deeply engaged in the optimal management of patients undergoing complex polypharmacy by assessing the clinical significance of potential drug-drug interactions (DDIs) in real-world settings and evaluating potentially inappropriate prescribing practices to improve medication safety. This work often emphasizes novel therapeutics, including long-acting formulations and biologics.

Furthermore, I am also interested in applying pharmacogenetic principles to inform personalized medicine approaches, tailoring pharmacotherapy to individual genetic profiles to enhance therapeutic efficacy while minimizing adverse effects.

Cattaneo D, Fusi M, Mariani C, Passerini M, Scandiffio L, Birindelli S, Merli S, Giorgi R, Gori A, Dolci A. Effect of body mass index on the timing of therapeutic drug monitoring-guided dalbavancin dosing in patients with osteoarticular infections. J Antimicrob Chemother. 2025 Apr 21:dkaf132. doi:10.1093/jac/dkaf132. Epub ahead of print. PMID: 40256850.
Cattaneo D, Ridolfo AL, Dalu D, Pruneri C, Giacomelli A, Cossu MV, Ruggieri L, Fasola C, Civati A, Dolci A, La Verde N, Antinori S, Gori A, Gervasoni C. Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience. Expert Opin Drug Metab Toxicol. 2025 Jun;21(6):729-736. doi: 10.1080/17425255.2025.2489393. Epub 2025 Apr 7. PMID: 40186615.
Cattaneo D, Fusi M, Cozzi V, Baldelli S, Bonini I, Gervasoni C, Clementi E. Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action? Clin Pharmacokinet. 2021 May;60(5):603-609. doi:10.1007/s40262-020-00964-1. Epub 2020 Nov 12. PMID: 33180272.
Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G; Mycophenolate Steroids Sparing (MYSS) Genetics Study Group. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol. 2009 Jun;20(6):1404-15. doi: 10.1681/ASN.2008080819. Epub 2009 May 21. PMID: 19470683; PMCID: PMC2689900.
Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep;62(3):1060-7. doi: 10.1046/j.1523-1755.2002.00531.x. PMID: 12164891.